| Patient Safety |
0 |
0.82 |
| Morphea |
0 |
0.99 |
| Child |
0 |
0.98 |
| Central Nervous System |
0 |
0.36 |
| Vasculitis |
0 |
0.3 |
| Central Nervous System Vasculitis |
0 |
0.28 |
| Pediatric Dermatology |
0 |
1 |
| Uveitis |
0 |
0.24 |
| COVID-19 |
0 |
0.22 |
| Hospital |
0 |
0.22 |
| Quality of Life |
0 |
0.22 |
| Seizure |
0 |
0.18 |
| Scleroderma |
0 |
0.15 |
| Chronic Disease |
0 |
0.13 |
| Hand |
0 |
0.13 |
| Laser |
0 |
0.13 |
| Pedal |
0 |
0.13 |
| Steroids |
0 |
0.13 |
| Headache |
0 |
0.1 |
| Arthritis |
0 |
0.09 |
| Birth |
0 |
0.09 |
| Brain |
0 |
0.09 |
| Cervical Region |
0 |
0.09 |
| Frontal Region |
0 |
0.09 |
| Muscle |
0 |
0.09 |
| Orbit |
0 |
0.09 |
| Port-Wine Stain |
0 |
0.09 |
| Tissue |
0 |
0.09 |
| Physical Medicine and Rehabilitation (PMR) |
0 |
0.08 |
| Medical Life |
0 |
0.07 |
| Burnout |
0 |
0.06 |
| Biologic Therapy |
0 |
0.05 |
| Complementary and Alternative Medicine |
0 |
0.05 |
| Wound Management |
0 |
0.05 |
| Adverse Effects |
0 |
0.04 |
| Antinuclear Antibody Positive |
0 |
0.04 |
| Biomarker |
0 |
0.04 |
| Blood |
0 |
0.04 |
| Burns |
0 |
0.04 |
| Cavernous Hemangioma |
0 |
0.04 |
| Corticosteroids |
0 |
0.04 |
| Dermatoses |
0 |
0.04 |
| Emesis |
0 |
0.04 |
| Face |
0 |
0.04 |
| Interleukin |
0 |
0.04 |
| Limb |
0 |
0.04 |
| Physical Therapy |
0 |
0.04 |
| Remission |
0 |
0.04 |
| Skin Lesion |
0 |
0.04 |
| T-Lymphocyte |
0 |
0.04 |
| Topical Medication |
0 |
0.04 |